



VILIN BIO MED LTD.

Unit-II, Khasra No. 85, Madhopur Village, Hazaratpur, Roorkee, Dist : Haridwar (Uttarakhand)
E-mail : vilinbiomedltd@yahoo.co.in

NOTICE

NOTICE IS HEREBY GIVEN THAT THE SIXTEENTH ANNUAL GENERAL MEETING OF THE MEMBERS OF M/S VILIN BIO MED LIMITED SHALL BE HELD ON FRIDAY, SEPTEMBER 30, 2022 AT 11:00 A.M. AT THE REGISTERED OFFICE OF THE COMPANY

Ordinary Business:

1. To receive, consider and adopt the Balance Sheet as at March 31, 2022, Statement of Profit and Loss for the period ended on that date together with the Reports of Directors and Auditor's thereon:

To consider and, if thought fit, to pass with or without modifications, the following Resolution as an Ordinary Resolution:

"RESOLVED THAT the Audited Financial Statements for the Financial Year ended March 31, 2022 containing the Audited Balance Sheet as at March 31, 2022, the Statement of Profit and Loss Account for the period ended on that date, the Cash Flow Statement and Notes to Accounts together with the Report of the Directors and Auditor's thereon be and are hereby approved and adopted.

RESOLVED FURTHER THAT the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."

Special Business

2. Regularization of Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) as Director of the Company:

To consider and, if thought fit, to pass with or without modifications, the following Resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 152, 160 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended from time to time, and pursuant to the recommendation of the Board of Directors, Ms. Padmaja Kalyani Sadhanala (DIN: 03096445), Additional Director of the Company, be and is hereby appointed as Director of the Company liable to retire by rotation.

RESOLVED FURTHER THAT the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."



3. Regularization of Mr. Viswa Prasad Sadhanala (DIN: 08068933) as Director of the Company:

To consider and, if thought fit, to pass with or without modifications, the following Resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 152, 160 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended from time to time, and pursuant to the recommendation of the Board of Directors, Mr. Viswa Prasad Sadhanala (DIN: 08068933), Additional Director of the Company, be and is hereby appointed as Director of the Company.

RESOLVED FURTHER THAT the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."

4. Appointment of Mr. Viswa Prasad Sadhanala (DIN: 08068933) as the Managing Director of the Company:

To consider and, if thought fit, to pass with or without modifications, the following Resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Schedule-V of the Companies Act, 2013, the Consent of the Members, be and is hereby accorded to appoint Mr. Viswa Prasad Sadhanala (DIN: 08068933), as the Managing Director of the Company for a term of five years with effect from October 1, 2022 at a remuneration detailed below:

- a. Overall Remuneration: Mr. Viswa Prasad Sadhanala (DIN: 08068933) shall be paid remuneration (i.e., Salary, Perquisites and Commission) up to Rs.75,000/- (Rupees Seventy-Five Thousand Only) Per Month.
- b. Minimum Remuneration: In the event of inadequacy or absence of Profits in any Financial Year, during the tenure of his office, he shall be paid the above remuneration as the Minimum Remuneration payable in accordance with the provisions of Part-II of Schedule-V of the Act and in accordance with the provisions of the Companies Act, 2013.
- c. The composition of the remuneration payable to Mr. Viswa Prasad Sadhanala (DIN: 08068933) may be varied as desired by him and accepted by the Board.
- d. He shall not be liable to retire by rotation.

RESOLVED FURTHER THAT the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."



5. Regularization of Mr. Anuj Bajpai (DIN: 08939135) as Director of the Company.

To consider and, if thought fit, to pass with or without modifications, the following Resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 152, 160 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended from time to time, and pursuant to the recommendation of the Board of Directors, Mr. Anuj Bajpai (DIN: 08939135), Additional Director of the Company be and is hereby appointed as Director of the Company.

RESOLVED FURTHER THAT the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."

6. Appointment of Mr. Anuj Bajpai (DIN: 08939135) as Whole Time Director of the Company

To consider and, if thought fit, to pass with or without modifications, the following Resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Schedule-V of the Companies Act, 2013, the Consent of the Members be and is hereby accorded to appoint Mr. Anuj Bajpai (DIN: 08939135) as the Whole Time Director of the Company for a term of three years with effect from October 1, 2022 at a remuneration detailed below:

- a. Overall Remuneration: Mr. Anuj Bajpai (DIN: 08939135) shall be paid remuneration (i.e., Salary, Perquisites and Commission) up to Rs.75,000/- (Rupees Seventy-Five Thousand Only) Per Month.
- b. Minimum Remuneration: In the event of inadequacy or absence of Profits in any Financial Year, during the tenure of his office, he shall be paid the above remuneration as the Minimum Remuneration payable in accordance with the provisions of Part-II of Schedule-V of the Act and in accordance with the provisions of the Companies Act, 2013.
- c. The composition of the remuneration payable to Mr. Anuj Bajpai (DIN: 08939135) may be varied as desired by him and accepted by the Board.
- d. He shall be liable to retire by rotation.

RESOLVED FURTHER THAT the Directors of the Company be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."



VILIN BIO MED LTD.

Unit-II, Khasra No. 85, Madhopur Village, Hazaratpur, Roorkee, Dist : Haridwar (Uttarakhand)
E-mail : vilinbiomedltd@yahoo.co.in

**By the Order of Board
For Vilin Bio Med Limited**

**Viswa Prasad Sadhanala
Additional Director
DIN: 08068933**

**Date: August 27, 2022
Place: Secunderabad**

NOTES:

1. A MEMBER ENTITLED TO VOTE IS ENTITLED TO APPOINT A PROXY, AND THE PROXY SO APPOINTED NEED NOT BE A MEMBER.
2. THE REGISTER OF MEMBER SHALL BE CLOSED FROM 28-09-2022 TO 30-09-2022 IN VIEW OF THE ANNUAL GENERAL MEETING OF THE COMPANY
2. EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF COMPANIES ACT, 2013 FORMS A PART OF THIS NOTICE.



Explanatory Statement

(Pursuant to Section 102 of Companies Act, 2013)

Item No. 2

Ms. Padmaja Kalyani Sadhanala was appointed as Additional Director with effect from December 1, 2021, in accordance with the provisions of Section 161 of the Companies Act, 2013 and the said Director holds office up to the date of ensuing Annual General Meeting of the Company. The Company has received notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Ms. Padmaja Kalyani Sadhanala as Director of the Company. Further, the Board is of the view that the appointment of Ms. Padmaja Kalyani Sadhanala, on the Company Board is desirable and would be beneficial to the Company and hence it recommends the said Resolution No. 2 for approval by the Members of the Company.

None of the Directors of the Company are in any way concerned or interested, in the said Resolution except Ms. Padmaja Kalyani Sadhanala, is concerned in the said Resolution. The Board recommends the said Resolution to be passed as an Ordinary Resolution.

Item No. 3 and 4

Mr. Viswa Prasad Sadhanala was appointed as an Additional Director with effect from December 1, 2021, in accordance with the provisions of Section 161 of the Companies Act, 2013 and the said Director holds office up to the date of ensuing Annual General Meeting of the Company. The Company has received notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Viswa Prasad Sadhanala as Director of the Company.

Further, the Board proposed to appoint Mr. Viswa Prasad Sadhanala as the Managing Director of the Company for a period of five years with effect from October 1, 2022 in compliance with the provisions of Sections 196, 197, 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Schedule-V of the Companies Act, 2013. Mr. Viswa Prasad Sadhanala is one of the Promoters of the Company and has experience of over twenty years in the fields of General Administration and Legal matters. The Board is of the view that his appointment would be beneficial to the Company. Hence it recommends passing the Resolutions as set out in item No. 3 and 4 for approval by the Members of the Company.

Except Mr. Viswa Prasad Sadhanala, none of the Directors of the Company is interested in the said Resolutions.



VILIN BIO MED LTD.

Unit-II, Khasra No. 85, Madhopur Village, Hazaratpur, Roorkee, Dist : Haridwar (Uttarakhand)
E-mail : vilinbiomedltd@yahoo.co.in

Item No. 5 and 6

Mr. Anuj Bajpai was appointed as Additional Director with effect from March 25, 2022, in accordance with the provisions of Section 161 of the Companies Act, 2013 and the said Director holds office up to the date of ensuing Annual General Meeting of the Company. The Company has received notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Anuj Bajpai as Director of the Company.

Further, the Board proposed to appoint Anuj Bajpai as the Whole Time Director of the Company for a period of three years with effect from October 1, 2022 in compliance with the provisions of Sections 196, 197, 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Schedule-V of the Companies Act, 2013. Mr. Anuj Bajpai is one of the Promoters of the Company and has experience of over twenty-five years in the Pharma Industry. The Board is of the view that his appointment would be beneficial to the Company and hence it recommends passing the Resolutions as set out in item No. 5 and 6 for approval by the Members of the Company.

Except Mr. Anuj Bajpai, none of the Directors of the Company is interested in the said Resolutions.

**By the Order of Board
For Vilin Bio Med Limited**

**Viswa Prasad Sadhanala
Additional Director
DIN: 08068933**

**Date: August 27, 2022
Place: Secunderabad**

VILIN BIO MED LIMITED
CIN: U24230TG2005PLC046689
Address: H.NO.6-61-1,1ST FLOOR, SHILPI COMPLEX,
DILSUKHNAGAR HYDERABAD TG 500035 IN
Email Id: vilinbiomedltd@yahoo.co.in
Ph: +91 93967 15292

BOARDS REPORT

Dear Members,

The Board takes pleasure in presenting herewith the Annual Report on the business of the Company together with the Financial Statements for the Financial Year ended March 31, 2022.

FINANCIAL HIGHLIGHTS

The following are the financial highlights of the Company:

(Amount in Rs. In Thousands)

Particulars	2021-22	2020-21
Revenue from operations	1,12,149.24	1,17,152.22
Other Income	41.56	35.85
Total Income	1,12,190.80	1,17,188.07
Finance Cost	5,061.20	4,421.07
Total Expenses	1,11,744.49	1,15,576.71
Profit Before Tax	446.31	1,611.36
Tax Expense	100	400
Profit After Tax	346.31	1,211.36

There has been no change in the nature of business of the Company.

DIVIDEND

The Board of directors did not recommend any dividend during the Financial Year.

TRANSFER TO RESERVES

The Company has not transferred any amounts to reserves during the year under review.

DEPOSITS

During the year under review, your Company has not accepted any deposits falling within the purview of Section 73 of the Companies Act, 2013.

DETAILS OF DIRECTORS OR KEY MANAGERIAL PERSONNEL

During the year under review, the following changes took place:

1. Mr. Anuj Bajpai (DIN: 08939135) was appointed as Additional Director of the Company w.e.f 25/03/2022.
2. Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) was appointed as Additional Director of the Company w.e.f 01/12/2021
3. Ms. Viswa Prasad Sadhanala (DIN 08068933) was appointed as Additional Director of the Company w.e.f 01/12/2021

Their appointment is recommended for regularization at the ensuing AGM.

Except as stated above, there were no changes in the Composition of Board during the year under review.

STATUTORY AUDITORS

M/s. Singh Yudhveer & Associates., Chartered Accountants (FRN: 011039C), were appointed as the statutory auditors of the Company for a period of 5 years till the conclusion of the Annual General Meeting of the Company to be held in the year 2024. Accordingly, the said auditors have carried out the statutory audit for the FY 2021-22.

AUDITORS' REPORT

The Auditors' Report does not contain any qualifications, observations or remarks. Notes to Accounts and Auditors remarks in their report are self-explanatory and do not call for any further comments.

There were no frauds reported by the statutory auditors of the Company.

COST RECORDS

The provisions of Cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013, are not applicable to the Company.

CORPORATE SOCIAL RESPONSIBILITY

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within the purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on corporate social responsibility.

RISK MANAGEMENT

The Risk Management is overseen by the Board of Directors of the Company on a continuous basis. The Board oversees Company's process and policies for determining risk tolerance and review management's measurement and comparison of overall risk tolerance to established levels. The Board is of the opinion that there are no material risks which threaten the very existence of the company.

INTERNAL FINANCIAL CONTROLS

The Company has adequate internal financial controls that commensurate with the size of the business of the Company.

DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134 (5) of the Companies Act, 2013 Your Directors' confirm that:

- i. In preparation of annual accounts for the financial year ended March 31, 2022 the applicable Accounting Standards have been followed along with proper explanation relating to material departures;
- ii. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the financial year ended March 31, 2022 and of the profit and loss of the Company for the year;
- iii. The Directors have taken proper and sufficient care for their maintenance of adequate accounting records in accordance with the provisions of the Companies Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities except that the Company is in the process of updating its fixed asset register;
- iv. The Directors had prepared the annual accounts on a going concern basis; and
- v. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE OUTGO

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is enclosed herewith as **Annexure-I**.

BOARD MEETINGS

During the year under review, 5 (five) board meetings were held on 25/06/2021, 05/09/2021, 29/11/2021, 01/12/2021 and 25/03/2022. All Directors attended all the Board Meetings as eligible.

PARTICULARS OF EMPLOYEES

The provisions of Section 197(12) of the Companies Act, 2013 are not applicable to the Company.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

During the year under review, the Company has not granted any Loans, given guarantees or made investments exceeding the limits under Section 186 of the Companies Act, 2013.

RELATED PARTY TRANSACTIONS

The Company has not entered into any related party transactions falling within the purview of Section 188 of the Companies Act, 2013 during the year under review.

COMPLIANCE OF SECRETARIAL STANDARDS

The Company has, during the year under review, complied with all the relevant provisions of the notified secretarial standards.

CONSTITUTION OF INTERNAL COMPLAINTS COMMITTEE

The Company is not required to formulate Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Also there were no cases filed/ registered pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Company has the requisite structure/policy under the said Act.

GENERAL

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

1. Issue of equity shares with differential rights as to dividend, voting or otherwise.
2. Issue of shares (including sweat equity shares) to employees of the Company under any scheme.
3. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Company's operations in future.
4. No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year and date of report.
5. The Company does not have any website.
6. There is no proceedings pending under the Insolvency and Bankruptcy Code, 2016 as at 31.03.2022. Certain case were filed against the Company, however the same have been settled and withdrawn.
7. There was no instance of one-time settlement with any bank or financial institution.

The other disclosures to be disclosed pursuant to Section 134 and other applicable provisions, if any of the Act and rules framed thereunder are not applicable to the Company.


ACKNOWLEDGEMENT

Your Directors place on record their appreciation of the continued patronage extended to the Company by bankers, dealers, customers, suppliers, employees and shareholders. The trust reposed in your Company by its esteemed customers helped stabilized growth during the year review.

Your Company also acknowledges the support and guidance received from its Bankers, other government agencies during the year under review and look forward to continuing support.

FOR VILIN BIOMED LTD. BOARD OF DIRECTOR

A. VENUGOPAL
MG. DIRECTOR
DIN-01918868
Managing Director

For VILIN BIO MIL

ANUJ BAJPAI
DIRECTOR
DIN-08939135

28.08.2022
Roorkee

**STATEMENT PURSUANT TO SECTION 134(3)(m) OF THE COMPANIES ACT, 2013
READ WITH RULE 8 OF THE COMPANIES (ACCOUNTS) RULES, 2014**

(A) Conservation of energy-

- (i) the steps taken or impact on conservation of energy: Nil
- (ii) the steps taken by the company for utilizing alternate sources of energy: Nil
- (iii) the capital investment on energy conservation equipment's: Nil

The Company's core activity is civil construction, which is not power intensive. However, the Company makes every effort to conserve the usage of power such as electricity, diesel, petrol, etc.

(B) Technology absorption-

- (i) the efforts made towards technology absorption: Nil
- (ii) the benefits derived like product improvement, cost reduction, product development or import substitution: Nil
- (iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-
 - (a) the details of technology imported: Nil
 - (b) the year of import: Nil
 - (c) whether the technology been fully absorbed: Nil
 - (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof: Nil
- (iv) the expenditure incurred on Research and Development: Nil

(C) Foreign exchange earnings and Outgo-

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows: Nil

For: VILIN BIOMED LTD.
BOARD OF DIRECTOR

A. VENUGOPAL
MG. DIRECTOR
DYN-01918868
Managing Director

For VILIN BIO ML

ANUJ BAJPAI
DIRECTOR
DIN-08939135

28.08.2022
Roorkees



Singh Yudhveer & Associates

Chartered Accountants

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF M/S VILIN BIOMED LIMITED

UDIN:- 22401054AXMDKM7290

Opinion

We have audited the financial statements of **M/S VILIN BIOMED LIMITED**, which comprise the Balance sheet as at 31st March 2022; and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2022, its profit/loss and its cash flows for the year ended on that date,

- In the case of the balance sheet, of the state of affairs of the company as at March 31, 2022
- In the case of the Profit and Loss Account, of the profit for the period ended on that date and
- In the case of cash flow statement, for the cash flows for the year ended on that date
- And the changes in equity for the year ended on that date

Basis for Opinion

We conducted our audit in accordance with the Accounting Standards (AS) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.


S. No.	Key Audit Matter	Auditor's Response
1.	Nil	Nil

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.



If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards (AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements


1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards (AS) specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.
 - g) With respect to the matter to be included in the Auditor's Report under section 197(16), In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under section 197(16) which are required to be commented upon by us.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



- iv. (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The management has represented, that, to the best of its knowledge and belief, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.
- v. No dividend have been declared or paid during the year by the company.

For **SINGH YUDHVEER & ASSOCIATES**
Chartered Accountants
(Firm's Registration No. : 011039C)

CA. YUDHVEER SINGH
Proprietor
(Membership No.: 401054)



Place: Roorkee
Date: 28/08/2022

UDIN:- 22401054AXMDKM7290

Annexure 'A'

UDIN:- 22401054AXMDKM7290


The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".

We report that:


- (i) (a) (A) The company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;
- (B) The company is maintaining proper records showing full particulars of intangible assets;
- (b) As explained to us, Property, Plant and Equipment have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification;
- (c) The title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the financial statements are held in the name of the company, except the following:-

Description of Property	Gross carrying value	Held in name of	Whether promoter, director or their relative or employee	Period held - indicate range, where appropriate	Reason for not being held in name of company
NIL					

- (d) The company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.
- (e) As explained to us, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- (ii) (a) As explained to us, physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancy of 10% or more in the aggregate for each class of inventory were noticed on physical verification of stocks by the management as compared to book records.
- (b) According to the information and explanation given to us and on the basis of our examination of the records of the company, the company has not been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not made any investments, provided guarantee, given security in the nature of loans, secured or unsecured to companies, firms, LLP or any other parties during the year the terms and conditions of which are prima facie prejudicial to the company's interest;
- (iv) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not given any loans or given guarantees, and security, as specified under Section 185 and 186 of the Companies Act, 2013 and the company has not provided any guarantee or security as specified under section 186 of the Companies Act, 2013.



- (v) The company has not accepted any deposits or amounts which are deemed to be deposits from public accordingly, clause 3(v) of the order is not applicable.
- (vi) As per information & explanation given by the management, the Central Govt. has not prescribed the maintenance of cost records sub-section (1) of section 148 of the Companies Act 2013 for the product manufactured by it. Accordingly, clause 3(vi) of the order is not applicable.
- (vii) (a) According to the records made available to us, company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. According to the information and explanation given to us there were no outstanding statutory dues as on 31st of March, 2022 for a period of more than six months from the date they became payable except Income Tax.
- (b) According to the information and explanations given to us, there is no statutory dues referred to in sub-clause (a) that have not been deposited on account of any dispute.
- (viii) According to the information and explanations given by the management, no transactions not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- (ix) (a) In our opinion and according to the information and explanations given by the management, the company did not have any loans or borrowings from any lender during the year. Accordingly clause 3(ix) (a) of the order is not applicable.
- (b) According to the information and explanations given by the management, the company is not declared willful defaulter by any bank or financial institution or other lender;
- (c) In our opinion and according to the information and explanations given by the management, the Company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained.
- (d) In our opinion and according to the information and explanations given by the management, funds raised on short term basis have not been utilized for long term purposes.
- (e) In our opinion and according to the information and explanations given by the management, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
- (f) In our opinion and according to the information and explanations given by the management, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.
- (x) (a) The company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year.
- (b) The company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.
- (xi) (a) According to the information and explanations given by the management, no fraud by the company or any fraud on the company has been noticed or reported during the year;
- (b) According to the information and explanations given by the management, No report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;
- (c) According to the information and explanations given to us by the management, no whistle-blower complaints had been received by the company.



- (xii) The company is not a Nidhi Company. Therefore, clause 3(xii) is not applicable on the company.
- (xiii) According to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, where applicable and the details have been disclosed in the financial statements,
- (xiv) (a) In our opinion and based on our examination, the company does not require to have an internal audit system.
- (xv) On the basis of the information and explanations given to us, in our opinion during the year the company has not entered into any non-cash transactions with directors or persons connected with him.
- (xvi) (a) In our Opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934).
(b) In our Opinion and based on our examination, the Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934,
(c) In our Opinion and based on our examination, the Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India.
(d) According to the information and explanations given by the management, the Group does not have any CIC as part of the Group.
- (xvii) Based on our examination, the company has not incurred cash losses in the financial year and in the immediately preceding financial year.
- (xviii) There has been resignation of the statutory auditors during the year and we have taken into consideration the issues, objections or concerns raised by the outgoing auditors.
- (xix) On the information obtained from the management and audit procedures performed and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date;
- (xx) Based on our examination, the provision of section 135 are not applicable on the company. Hence this clause is not applicable on the company.

For **SINGH YUDHVEER & ASSOCIATES**
Chartered Accountants
(Firm's Registration No. : 011039C)

CA. YUDHVEER SINGH
Proprietor
(Membership No.: 401054)

Place: Roorkee
Date: 28/08/2022

UDIN:- 22401054AXMDKM7290



Annexure 'B'

Report on Internal Financial Controls with reference to financial statements

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **M/S VILIN BIOMED LIMITED** as of March 31, 2022 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility


Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:




1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **SINGH YUDHVEER & ASSOCIATES**
Chartered Accountants
(Firm's Registration No. : 011039C)

CA. YUDHVEER SINGH
Proprietor
(Membership No. : 401054)



Place: Roorkee
Date: 28/08/2022

UDIN:- 22401054AXMDKM7290

VILIN BIO-MED LIMITED
 REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
 HYDERABAD, TELANGANA - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DISTT - HARIDWAR, UTTARAKHAND
 CIN :- U24230TG2005PLC046689

BALANCE SHEET AS AT 31st MARCH 2022

PARTICULARS		NOTE NO.	AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
I.	EQUITY AND LIABILITIES			
1	Shareholders' funds			
	(a) Share capital	2	33,000,000.00	33,000,000.00
	(b) Reserves and surplus	3	40,925,782.25	40,579,472.10
2	Share application money pending allotment		-	-
3	Non-current liabilities			
	(a) Long-term borrowings	4	7,339,671.00	10,157,861.94
	(b) Deferred tax liabilities (Net)	-	616,158.71	616,158.71
4	Current liabilities			
	(a) Short-term borrowings	5	45,656,258.00	45,000,000.00
	(b) Trade payables	6	6,412,361.73	8,168,769.64
	(c) Other current liabilities	7	1,382,658.00	842,167.00
	(d) Short-term provisions	8	250,000.00	550,000.00
TOTAL			135,582,889.69	138,914,429.39
II.	ASSETS			
1	Non-current assets			
	(a) Fixed assets			
	(i) Tangible Assets	9	16,495,527.92	18,689,299.27
	(b) Long-term loans and advances	10	485,213.00	485,213.00
	(c) Other non-current assets		-	-
2	Current assets			
	(a) Inventories	11	22,837,612.00	20,641,902.00
	(b) Trade receivables	12	77,864,590.42	76,451,594.29
	(c) Cash and cash equivalents	13	389,752.00	465,257.00
	(d) Short-term loans and advances	14	17,510,194.35	22,181,164.32
TOTAL			135,582,889.69	138,914,429.89


For VILIN BIO-MED LIMITED
 FOR & ON BEHALF OF THE BOARD OF DIRECTOR

A. VENUGOPAL
 MG. DIRECTOR
 DIN-01918868
 12-5-14/20 FLAT NO.-T-3
 GAOTHAMINAGAR, MANCHERIAL
 ADILABAD, TELANGANA-504208

PLACE: ROORKEE
 DATE: 28-08-2022
 UDIN: 22401054AXMDKM7290

For ROORKEE, UTTARAKHAND
 AS PER OUR SEPARATE REPORT OF EVEN DATE ATTACHED
 FOR SINGH YUDHVEER & ASSOCIATES
 CHARTERED ACCOUNTANTS

ANUJ BAJPAI
 DIRECTOR
 DIN-08939135
 B/3, MAHAVIR ENCLAVE, PUNAWA WALLEE
 ROORKEE-247667, UTTARAKHAND



YUDHVEER SINGH
 PROPRIETOR
 M. NO. 401054

VILIN BIO-MED LIMITED
REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
HYDERABAD, TELANGANA - 500035
WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
DISTT - HARIDWAR, UTTARAKHAND
CIN :- U24230TG2005PLC046689

STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31st MARCH 2022

PARTICULARS		NOTE NO.	AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
I.	Revenue from operations	15	112,149,239.10	117,152,222.49
II.	Other income	16	41,562.00	35,846.76
III.	Total Revenue (I + II)		112,190,801.10	117,188,069.25
IV.	Expenses:			
	Cost of materials consumed	17	88,766,966.40	90,628,316.57
	Change In Inventories of Finished Good, Work In Progress	18	(87,576.00)	(242,205.00)
	Employee benefits expense	19	9,990,742.00	10,612,689.44
	Finance costs	20	5,061,200.98	4,421,070.00
	Depreciation and amortization expense	9	2,193,770.86	2,569,998.82
	Other expenses	21	5,819,386.71	7,586,836.81
	Total expenses		111,744,490.95	115,576,706.64
V.	Profit before exceptional and extraordinary items and tax (III-IV)		446,310.15	1,611,362.61
VI.	Exceptional items		-	-
VII.	Profit before extraordinary items and tax (V - VI)		446,310.15	1,611,362.61
VIII.	Extraordinary Items		-	-
IX.	Profit before tax (VII- VIII)		446,310.15	1,611,362.61
X	Tax expense:		100,000.00	400,000.00
	(1) Current tax		-	-
	(2) Deferred tax		-	-
	(3) Previous Year Tax		-	-
XI	Profit (Loss) for the period from continuing operations (VII-VIII)		346,310.15	1,211,362.61
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations/ Income Tax for Earlier Years		-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		-	-
XV	Profit (Loss) for the period (XI + XIV)		346,310.15	1,211,362.61
XVI	Earnings per equity share:			
	(1) Basic		0.10	0.37
	(2) Diluted		0.10	0.37

FOR & ON BEHALF OF THE BOARD OF DIRECTOR

A. VENUGOPAL
 MG. DIRECTOR
 DIN-01918868
 12-5-14/20 FLAT NO.-T-3
 GAOTHAMINAGAR, MANCHERIAL
 ADILABAD, TELANGANA-504208

ANUJ BAJPAI
 DIRECTOR
 DIN-08939135
 B/3, MAHAVIR ENCLAVE, PURVA WALL,
 ROORKEE-247667, UTTARAKHAND

AS PER OUR SEPARATE REPORT OF EVEN DATE ATTACHED
 FOR SINGH YUDHVEER & ASSOCIATES
 CHARTERED ACCOUNTANTS



YUDHVEER SINGH
 PROPRIETOR
 M. NO. 401054

PLACE: ROORKEE
 DATE: 28-08-2022
 UDIN: 22401054AXMDKM7290

VILIN BIO-MED LIMITED
REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
HYDERABAD, TELANGANA - 500035
WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF PROFIT AS AT 31ST MARCH 2022

PARTICULARS	AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
NOTE NO. -21		
OTHER EXPENSES		
Manufacturing Exp.:-		
Freight Inward	62,606.00	181,869.63
Consumable Stores	92,297.00	86,363.00
Generator Runing & Maintenance Expenses	431,863.00	554,040.00
Lab Testing Charges	281,404.80	342,830.00
Drug Office Expenses	129,512.00	118,000.00
Power Expenses	1,190,595.00	1,401,569.38
Others:-		
Insurance Charges	192,635.00	14,865.00
Freight Outward	15,268.00	12,220.00
Miscellaneous Expenses	1,538.00	1,753.00
Printing & Stationary	42,102.00	49,852.00
Office & General Expenses	511,082.46	470,907.96
Postage & Telegram	19,874.00	19,341.00
Professional Fee Expenses	295,600.00	218,000.00
Repairs to Plant & Machinery	509,034.00	570,319.98
Repair & Maintenance Other	380,176.00	440,201.00
Legal Exp.	85,724.00	81,500.00
Telephone Expenses	55,417.93	63,191.00
Travelling & Conveyance Expenses (Including Director's Travelling)	313,065.11	320,443.00
Security Expenses	679,852.00	670,013.00
Vehicle Running & Maintenance	201,302.76	168,950.00
Rate Diffrence/ Rebate & Discount	91,816.00	1,817,370.00
Festival Expenses	2,596.00	3,120.00
Audit Fee	150,000.00	150,000.00
Business Promotion	82,500.00	54,000.00
Short & Excess/ Recovery	1,525.65	(223,882.14)
TOTAL	5,819,386.71	7,586,836.81

For. VILIN BIOMED LTD.

A. Ull
Managing Director

For. VILIN BIOMED LTD

Abhishek
Director



**M/S VILIN BIO-MED LIMITED,
REGD. OFF: H. NO. 6-61-1,1ST FLOOR,
SHILPI COMPLEX DILSUKHNAGAR,
HYDERABAD, ANDHRA PRADESH-500035.
WORKS: KH. NO. 85, VILL. MADHOPUR HAZRATPUR,
ROORKEE-247667 (U.K.),**

Note: 1

SIGNIFICANT ACCOUNTING POLICIES:

I. Basis of preparation of financial statements

The financial statements are prepared under the historical cost convention, in accordance with the Indian Generally Accepted Accounting Principles comprising the mandatory accounting standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 1956/2013 on accrual basis as adopted consistently by the company. All Assets and Liabilities have been classification as current or non-current as per the Company's normal operating cycle and other criteria set out in the revised schedule III of the Companies Act, 2013. For the purpose of current and non-current classification of assets and liabilities, the company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

II. System of Accounting

- i) The company follows the mercantile system of accounting and recognizes income and expenditure on an accrual basis except in case of significant uncertainties.
- ii) Financial statements are based on historical cost. These costs are not adjusted to reflect the impact of changing value in the purchasing power of money.
- iii) Estimates and assumptions used in the preparation of the financial statements and disclosures are based upon management's evaluation of the relevant facts and circumstances as of the date of the financial Statements, which may differ from the actual results at a subsequent date.

III. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates. Adjustments as a result of differences between actual and estimates are prospectively made.

IV. Revenue Recognition

Income


The Company recognize income on accrual basis. However, Where the ultimate collection of the same lacks' reasonable certainty, revenue recognition is postponed to the extent of uncertainty.

V. Fixed Assets:

Fixed Assets are stated at cost less accumulated depreciation. Cost includes all expenses incurred to bring the assets to its present location and condition.

VI. Depreciation

Depreciation (except on land which is not depreciated) is provided as per the provisions of The Companies Act 2013 which requires companies to compute the Depreciation in accordance with the Schedule II to the Companies Act which provides useful lives to compute the Depreciation. Depreciation on additions is pro-rata basis.



For VILIN BIOMED LTD.
A. [Signature]
Managing Director

For VILIN BIOMED LTD.
AB [Signature]
Director

VII. Related parties Transaction as per AS-18 are as under.

Nature of Transaction	S.NO	Name & Relation with Party	AMOUNT OF TRANSACTION (RS.)
REMUNERATION	1).	VENU GOPAL (MG. DIRECTOR)	1500000

VIII. Foreign Exchange Transactions

Transactions in foreign currencies are recorded at exchange rates prevailing on the date of the respective transactions. Current assets and current liabilities denominated in foreign currency are translated at the exchange rate prevailing at the date of balance sheet. The resulting difference between the rate prevailing on the date of transaction and on the date of settlement as also on translation of current assets and current liabilities (other than those related to fixed assets where it is adjusted to the cost of acquisition thereof) at the end of the year is recognized at the income or the expense as the case may be.

IX. Valuation of Inventories

Inventories are valued at cost or net realizable value whichever is lower. Cost of inventories comprise of all costs of purchase and other cost incurred in bringing the inventory to present location and condition.

X. Employee Benefits

The company is not applying Accounting Standard -15. Employee Benefits for future are accounting on cash

XI. Impairment of assets:

In the opinion of the company management there is no impairment to the assets to which accounting standard - 28 "Impairment of assets" applied requiring any revenue recognition.

XII. Borrowing Costs

The company is applying Accounting Standard-16.

As per AS-16, Financing/ Borrowing cost attributable to acquisition and / or construction of qualifying assets is to be capitalized as a part of the cost of such assets up to the date such assets are ready for their intended use. Other financing / Borrowing costs should be charged to profit & loss account.

XIII. Income-Tax

Income Tax expenses comprise of the Current Income Tax, deferred tax charge or credit.


Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of Income Tax Act, 1961 as applicable to the financial year.

Deferred Taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier year.

Deferred tax is measured based on the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

For MTD
A. Upp
Director

AS-11
Director



XIV. Provisions, Contingent Liabilities, and Contingent Assets

A provision is recognized when the company has a present obligation as a result of past event, it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at the balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not recognized but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.



For M.A. Shrivastava
A. [Signature]
Director

M.A. SHRIVASTAVA
A. [Signature]
Director

VILIN BIO-MED LIMITED
REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
HYDERABAD, TELANGANA - 500035
WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2022

NOTE NO. 2
SHARE CAPITAL:

(A) Authorised, Issued, Subscribed & Paid- up Share Capital:-

PARTICULARS	AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
Authorised Share Capital (33,00,000 Equity Shares of RS. 10/- Each)	33,00,000.00	33,00,000.00
Issued , Subscribed and Paid-up Capital (33,00,000 Equity Shares of RS. 10/- Each)	33,00,000.00	33,00,000.00
TOTAL	33,00,000.00	33,00,000.00

(B) Reconciliation of the Number of Share Outstanding:-

PARTICULARS	AS AT 31st MARCH 2022	AS AT 31st MARCH 2021
	NUMBER	NUMBER
Equity Shares Outstanding at the beginning of the year Add: Equity Shares allotted during the year	3,300,000	3,300,000
Equity shares outstanding at the end of the year	3,300,000	3,300,000

(C) Shareholders Holding More than 5% Shares of the Company:-

NAME OF SHAREHOLDERS	CLASS OF SHARES	AS AT 31st MARCH 2022		AS AT 31st MARCH 2021	
		NUMBER	%	NUMBER	%
(i) Akki Reddy Pradeep Reddy	Equity Shares	455,882	13.81	455,882	13.81
(ii) Merugu Ramesh	Equity Shares	389,706	11.81	389,706	11.81
(iii) Roopi Reddy Srikanth Reddy	Equity Shares	370,589	11.23	370,589	11.23
(iv) Merugu Vanitha	Equity Shares	270,294	8.19	270,294	8.19
(v) A. Venugopal	Equity Shares	262,118	7.94	262,118	7.94
(vi) Nalla Surender Reddy	Equity Shares	212,353	6.43	212,353	6.43
(vii) Akki Reddy Namratha Reddy	Equity Shares	204,118	6.19	204,118	6.19
(viii) B. Meghamala	Equity Shares	170,588	5.17	170,588	5.17

Rights, Preferences and Restrictions attached to each class of Shares and Terms of redemption:-

- i. The company has only one class of shares referred as equity shares. The equity share are having a par value of Rs. 10/- each. Every holder of equity share is entitled to one vote per share in respect of all matters submitted to vote in the shareholders's meeting.
- ii. In the event of liquidation of the company, the holder of equity shares will be entitled the receive the remaining assets of the company after distribution of preferential amounts. The distribution will be in the portion of the number of equity shares held by the shareholders.

Note:- During last 5 years immediately preceding the balance sheet date , No equity share or preference shares has been issued pursuant to any contract without payment being received in cash. Further the company has neither allotted any share by way of bonus shares nor it had bought back any equity or preference share during aforesaid period of 5 Years.

For VILIN BIOMED LTD

A. [Signature]
 Managing Director

For VILIN BIOMED LTD

A. [Signature]
 Director



VILIN BIO-MED LIMITED
 REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
 HYDERABAD, TELANGANA - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DISTT - HARIDWAR, UTTARAKHAND
 CIN :- U24230TG2005PLC046689

NOTE ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2022

PARTICULARES	AS AT 1st APRIL 2021 (IN RS.)	ADDITIONS / CREATED DURING THE YEAR	Deductions During the Year	AS AT 31st MARCH 2022(IN RS.)
NOTE NO - 3				
RESERVE & SURPLUS				
CAPITAL RESERVE (CAPITAL INVESTMENT SUBSIDY)	2,255,567.00	-	-	2,255,567.00
Total(A)	2,255,567.00	-	-	2,255,567.00
SURPLUS AS PER PROFIT & LOSS ACCOUNT	38,323,905.10	346,310.15	-	38,670,215.25
Total(B)	38,323,905.10	346,310.15	-	38,670,215.25
Total(A+B)	40,579,472.10	346,310.15	-	40,925,782.25

For VILIN BIO-MED LIMITED
A. Uppal
 Managing Director



For VILIN BIO-MED LIMITED
Abhishek
 Director

VILIN BIO-MED LIMITED
 REGD. OFF: H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
 HYDERABAD, TELANGANA - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DIST - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2022

PARTICULARS		AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
SHORT-TERM BORROWINGS			
(A) SECURED LOAN:-			
Loans From Bank			
P.N.B. Rām Nagar, Roorkee CC - A/C-16831			
[Secured against Hypothecation of Stock and Book Debts]			
(a) The company has availed CC Limit facility from PNB Bank, Ramnagar ROORKEE that is primarily secured against hypothecation of All types of Stocks, Current Assets & Equitable mortgage on Factory Land & building at interest rate ranging from 9.5% to 11% P.A. Interest is charged on monthly basis, which is repayable on demand.		45,656,258.00	45,000,000.00
TOTAL		45,656,258.00	45,000,000.00

NOTE NO. -5

SHORT-TERM BORROWINGS

(A) SECURED LOAN:-

Loans From Bank
 P.N.B. Rām Nagar, Roorkee CC - A/C-16831
 [Secured against Hypothecation of Stock and Book Debts]

(a) The company has availed CC Limit facility from PNB Bank, Ramnagar ROORKEE that is primarily secured against hypothecation of All types of Stocks, Current Assets & Equitable mortgage on Factory Land & building at interest rate ranging from 9.5% to 11% P.A. Interest is charged on monthly basis, which is repayable on demand.



FOR VILIN BIOMED LTD
 Director

FOR VILIN BIOMED LTD.
 Managing Director

VILIN BIO-MED LIMITED
 REGD. OFF: H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
 HYDERABAD, TELANGANA - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DIST - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2022

PARTICULARS		AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
LONG-TERM BORROWINGS			
SECURED LOAN:-			
Loans From Bank			
P.N.B. - GECL TL-A/C-3898001L00000270			
P.N.B. - 195 A/C			
Note:- Company during the year availed GECL Term Loan which is secured against Govt. guarantee under Covid-19 scheme bearing interest @ 7.65% P.A.			
TOTAL		7,339,671.00	10,157,861.94

NOTE NO. -4



Director
 VILIN BIO-MED LTD

Managing Director
 VILIN BIO-MED LTD

VILIN BIO-MED LIMITED
 REGD. OFF: H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
 HYDERABAD, TELANGANA - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2022

PARTICULARS		AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
NOTE NO.-6			
TRADE PAYABLE			
For Purchases & Others		6,412,361.73	8,168,769.64
TOTAL		6,412,361.73	8,168,769.64
NOTE NO.-7			
OTHER CURRENT LIABILITIES			
Expenses Payable		1,382,658.00	842,167.00
TOTAL		1,382,658.00	842,167.00
NOTE NO.-8			
SHORT TERM PROVISION			
Provision For Income Tax		100,000.00	400,000.00
Provision For Audit Fee		150,000.00	150,000.00
TOTAL		250,000.00	550,000.00



FOR VILIN BIOMED LTD
 Director

FOR VILIN BIOMED LTD.
 Managing Director


M/S VILIN BIOMED LIMITED
 REGD OFF : H.NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX
 DILSUKHINAGAR, HYDERABAD, ANDHRA PRADESH - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DISTT - HARIDWAR, UTTARAKHAND

STATEMENT OF FIXED (TANGIBLE) ASSETS ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2022

Note No. -9

PARTICULARS	GROSS BLOCK				NET BLOCK						
	BALANCE AS ON 01.04.2021	ADDITIONS UP TO 30.09.2021	ADDITIONS AFTER 30.09.2021	SALE/ TRANSFER	TOTAL AS ON 31.03.2022	BALANCE AS ON 01.04.2021	FOR THE YEAR	ADJUSTMENT FOR SALE	TOTAL AS ON 31.03.2022	BALANCE AS ON 31.03.2022	BALANCE AS ON 31.03.2021
LAND	2,115,400.00	-	-	-	2,115,400.00	-	-	-	-	2,115,400.00	2,115,400.00
BUILDING	34,899,407.00	-	-	-	34,899,407.00	24,514,049.54	1,029,407.58	-	25,543,457.12	9,355,949.88	10,385,357.46
FURNITURE & FIXTURE	1,596,291.00	-	-	-	1,596,291.00	1,333,711.97	76,372.24	-	1,410,084.21	186,206.79	262,579.03
PLANT & MACHINERY	52,942,878.54	-	-	-	52,942,878.54	47,123,277.95	1,080,838.00	-	48,204,115.95	4,738,762.59	5,819,600.59
COMPUTERS	460,746.00	-	-	-	460,746.00	443,665.00	-	-	443,665.00	17,081.00	17,081.00
OFFICE EQUIPMENT	367,657.60	-	-	-	367,657.60	343,501.87	4,410.35	-	347,912.22	19,745.38	24,155.73
VEHICLE	1,170,875.00	-	-	-	1,170,875.00	1,104,750.03	2,742.69	-	1,107,492.72	63,382.28	66,124.97
TOTAL (RS.)	93,553,255.14	-	-	-	93,553,255.14	74,862,956.36	2,193,770.86	-	77,056,727.22	16,495,527.92	18,690,298.78

For VILIN BIOMED LTD. Managing Director
 For VILIN BIOMED LTD. Director





FOR VILIN BIOMED LTD
Director

FOR VILIN BIOMED LTD
Managing Director

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2022		PARTICULARS	
		AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
VILIN BIO-MED LIMITED			
REGD. OFF: H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR			
HYDERABAD, TELANGANA - 500035			
WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667			
DISTT - HARIDWAR, UTTARAKHAND			
NOTE NO. -10			
LONG TERM LOAN AND ADVANCE		485,213.00	485,213.00
Earnest Money & Security			
TOTAL		485,213.00	485,213.00
NOTE NO. -11			
INVENTORIES		19,973,586.00	17,865,452.00
As taken value certified by the management:			
Raw Materials & Packing Materials		754,861.00	790,550.00
Semi Finished Good		2,109,165.00	1,985,900.00
Finished Good			
TOTAL		22,837,612.00	20,641,902.00
NOTE NO. -12			
TRADE RECEIVABLE		4,678,955.00	4,256,850.00
RECEIVABLES EXCEEDING SIX MONTH			
OTHERS		73,185,635.42	72,194,744.29
TOTAL		77,864,590.42	76,451,594.29
NOTE NO. -13			
CASH AND BANK BALANCES		389,752.00	465,257.00
Cash In Hand			
P.M.B Current A/C No. - 3898002100013041		81,520.95	-
TOTAL		389,752.00	465,257.00
NOTE NO. -14			
SHORT TERM LOAN & ADVANCES		8,320,005.35	12,681,459.32
Sundry Advances			
GST ITC		9,190,189.00	9,499,705.00
TOTAL		17,510,194.35	22,181,164.32

VILIN BIO-MED LIMITED
 REGD. OFF: H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
 HYDERABAD, TELANGANA - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF PROFIT AS AT 31ST MARCH 2022

PARTICULARS		AS AT 31st MARCH 2022 (IN RS.)	AS AT 31st MARCH 2021 (IN RS.)
REVENUE FROM OPERATIONS			
Net Sales		112,149,239.10	117,152,222.49
TOTAL			
NOTE NO.-15			
OTHER INCOME			
Other Income		41,562.00	35,846.76
Total			
NOTE NO.-17			
COST OF MATERIAL CONSUMED			
Opening Stock	17,865,452.00	18,561,733.00	
Add: Purchase Net	90,875,100.40	89,932,035.57	
Less: Closing Stock	19,973,586.00	17,865,452.00	
TOTAL			
NOTE NO.-18			
CHANGES IN INVENTORY OF FINISHED GOOD WORK IN PROGRESS AND STOCK IN TRADE			
Increase/ Decrease in Stock			
[A] Closing Stock	754,861.00	790,550.00	
Work In Progress	2,109,165.00	1,985,900.00	
Finished Good	2,864,026.00	2,776,450.00	
TOTAL			
[B] Opening Stock	790,550.00	845,655.00	
Work In Progress	1,985,900.00	1,688,590.00	
Finished Good	2,776,450.00	2,534,245.00	
TOTAL			
Net Increase/ (Decrease) [A]-[B]		(87,576.00)	(242,205.00)



For VILIN BIOMED LTD
 Director

For VILIN BIOMED LTD
 Managing Director

VILIN BIO-MED LIMITED
 REGD. OFF: H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR
 HYDERABAD, TELANGANA - 500035
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF PROFIT AS AT 31ST MARCH 2022

PARTICULARS		AS AT 31ST MARCH 2022 (IN RS.)	AS AT 31ST MARCH 2021 (IN RS.)
EMPLOYEE BENEFITS EXPENSES			
Salary & Wages	8,016,371.00	1,500,000.00	8,436,683.44
Directors Remuneration	366,613.00	6,000.00	527,833.00
Staff Welfare/ Labour Uniform	6,000.00	79,583.00	6,000.00
EPF Administration Charges	22,175.00	119,371.00	22,802.00
EPF Contribution	79,583.00	22,175.00	119,371.00
ESIC Contribution	22,175.00	22,175.00	22,802.00
TOTAL			
NOTE NO. -19			
FINANCE COST			
Interest On CC Limit	4,306,325.00	319.92	3,584,065.00
Bank Interest - Other	644,194.00	110,362.06	482,479.00
Bank Interest T/L 270A/C	110,362.06	271,263.00	271,263.00
Bank Charges	319.92	83,263.00	83,263.00
TOTAL			
NOTE NO. -20			



FOR VILIN BIOMED LTD
 Director

FOR VILIN BIOMED LTD
 Managing Director